The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

PRESENTATION
Phase 2 and Long-Term Extension Results from Treatment With the Orexin 2 Receptor Agonist Alixorexton Demonstrated Clinically Meaningful Improvements in Symptoms of Narcolepsy Type 1 and 2
Author(s):

Giuseppe Plazzi1,2

1IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 2University of Modena and Reggio-Emilia, Modena, Italy

Content available until 10/20/2029